The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Despite the devastating worldwide human and economic tolls of the COVID-19 crisis, it has
created some positive economic and financial surprises and opportunities for research. This …

Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …

Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …